EUVIMEDEUVIMED entdecken
Crossref

Clinicopathological and prognostic significance of immune-related PD-L1 expression in locally advanced gastric cancer with HER2-low expression

Fang Li, Pei Zhang, Huirui Zhang, Huiyan Deng, Xu Wang, Junying Liu, Kun Wang, Yao Liu, Shi Li, Yan Ding

Pathology - Research and Practice · 2026-10 · 286 · 156583

DOI: 10.1016/j.prp.2026.156583 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pathology - Research and Practice, 2026-10. Verfasst von Fang Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China. Hauptthemen laut MEDLINE: Stomach Neoplasms, B7-H1 Antigen, Erb-b2 Receptor Tyrosine Kinases, Biomarkers, Tumor. Die Arbeit nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gastric cancer (GC) is a highly invasive and heterogeneous malignant tumor. HER2-low GC is considered a biologically and clinically important intermediate subtype. Clarifying its clinicopathological features, genetic alterations, and tumor immune microenvironment is critical for improving clinical management. This study retrospectively enrolled 576 patients with HER2-non-amplified locally advanced GC(LAGC) who underwent surgical resection between January 2017 and December 2019. Patients were classified into HER2-low and HER2-zero groups using immunohistochemistry and in situ hybridization. Based on the Asian Cancer Research Group (ACRG) classification and PD-L1 expression, we analyzed the associations of HER2-low status with clinicopathological features, PD-L1 expression, and prognosis using Kaplan-Meier and Cox regression. Among 576 patients, 268 (46.53%) were HER2-low. HER2-low was more frequent in tumors ≤ 4.61 cm and intestinal-type GC (p < 0.001). PD-L1 positive rate was 49.65%, correlated with pN stage, vascular invasion, and ACRG subtype (p < 0.05). HER2-low tumors showed significantly higher PD-L1 positivity (p < 0.001). Independent prognostic factors for 5-year overall survival included tumor invasion depth, lymph node metastasis, and TNM stage (p < 0.001). HER2-low GC helps refine GC classification and is associated with higher PD-L1 expression, supporting immunotherapy strategies. Further research is needed to explore its clinical and therapeutic value in personalized precision treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsB7-H1 AntigenErb-b2 Receptor Tyrosine KinasesBiomarkers, TumorHumansFemalePrognosisMiddle AgedMaleRetrospective StudiesAgedTumor MicroenvironmentAdult

Stichwörter der Autor:innen

HER2-low expressionLAGCPD-L1 expressionPrognostic

Substanzen

B7-H1 AntigenErb-b2 Receptor Tyrosine KinasesCD274 protein, humanBiomarkers, TumorERBB2 protein, human

Autor:innen und Institutionen

  • Department of Pathology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
  • Department of Pathology, Affiliated Hospital of Hebei University, Baoding, China.
  • Department of Pathology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China. Electronic address: 47800847@hebmu.edu.cn.

Zitieren

APA

Li, F., Zhang, P., Zhang, H., Deng, H., Wang, X., Liu, J., Wang, K., Liu, Y., Li, S., & Ding, Y. (2026). Clinicopathological and prognostic significance of immune-related PD-L1 expression in locally advanced gastric cancer with HER2-low expression. Pathology - Research and Practice, 286, 156583. https://doi.org/10.1016/j.prp.2026.156583

Vancouver

Li F, Zhang P, Zhang H, Deng H, Wang X, Liu J, et al. Clinicopathological and prognostic significance of immune-related PD-L1 expression in locally advanced gastric cancer with HER2-low expression. Pathology - Research and Practice. 2026;286:156583. doi:10.1016/j.prp.2026.156583

BibTeX
@article{Li2026,
  author = {Li, Fang and Zhang, Pei and Zhang, Huirui and Deng, Huiyan and Wang, Xu and Liu, Junying and Wang, Kun and Liu, Yao and Li, Shi and Ding, Yan},
  title = {Clinicopathological and prognostic significance of immune-related PD-L1 expression in locally advanced gastric cancer with HER2-low expression},
  journal = {Pathology - Research and Practice},
  year = {2026},
  volume = {286},
  pages = {156583},
  doi = {10.1016/j.prp.2026.156583}
}
Kostenlos starten →